Matinas BioPharma (MTNB) has released an update.
Matinas BioPharma Holdings, Inc. has announced a significant milestone in reaching an agreement with the FDA on a Phase 3 trial for their MAT2203 drug, aimed at treating invasive aspergillosis in patients with limited options. This major trial, named ORALTO, will test the efficacy and safety of MAT2203 as a more convenient oral medication compared to the current standard IV treatment. The study will target a primary endpoint of reducing mortality at 42 days post-treatment, with secondary goals evaluating treatment-related toxicities, long-term survival, and impacts on healthcare resources and patient quality of life. With an anticipated enrollment of about 216 adults, the international trial is set to begin in the latter half of 2024 and will span across various global regions, marking a crucial step towards potential new treatment avenues for aspergillosis sufferers.
For further insights into MTNB stock, check out TipRanks’ Stock Analysis page.
